<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907749</url>
  </required_header>
  <id_info>
    <org_study_id>Yang-20160905</org_study_id>
    <nct_id>NCT02907749</nct_id>
  </id_info>
  <brief_title>Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis</brief_title>
  <acronym>FP-PH</acronym>
  <official_title>Effects of Spironolactone on Fibrosis Progression and Portal Hypertension in Patients With Compensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changqing Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tongji Hospital, Tongji University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of spironolactone on liver fibrosis
      progression and portal hypertension in patients with compensated cirrhosis. The patients were
      nonrandomized according to the medical conditions determined by the physicians, in 3 arms
      (spironolactone start from 40mg once daily and increase every week with a maximum dose as
      100mg once daily, carvedilol start from 6.25mg once daily and increase to 12.5mg once daily
      in next week if being tolerated, spironolactone in combination with carvedilol:
      spironolactone is added when carvedilol has reached the most tolerated dose). Portal pressure
      gradient by virtual hepatic venous pressure gradients based on enhanced CT, and liver
      elasticity by Fibroscan Medical Device are documented at baseline level and every six months
      after the treatment. Changes in serum fibrosis markers and liver function are monitored
      before and every 3 months after the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver elasticity as assessed by Fibroscan</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal pressure gradient(PPG) as determined by a virtual PPG (vPPG) based on CT angiography and Doppler ultrasound</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of cirrhosis-related complications as recorded in patient history</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone and Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone Pill</intervention_name>
    <description>spironolactone starts from 40mg once daily and increase every week with a maximum dose as 100mg once daily</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>carvedilol starts from 6.25mg once daily and increase to 12.5mg once daily in next week if being tolerated</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone and Carvedilol</intervention_name>
    <description>spironolactone is added when carvedilol has reached the most tolerated dose</description>
    <arm_group_label>Spironolactone and Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proven compensated cirrhosis based on histology or unequivocal clinical, sonographic
             and laboratory findings

          -  Proven portal hypertension by calculated virtual HVPG &gt;12mmHg based on enhanced CT

          -  Child-Pugh score &lt; 9

          -  Suspension of alcohol intake for at least 6 weeks before enrollment

        Exclusion Criteria:

          -  Treatment with angiotensin II receptor antagonists or angiotensin converting enzyme
             inhibitors in the last 2 months

          -  Renal insufficiency

          -  Hepatic encephalopathy at stage 2

          -  Contraindications to beta-blockers or spironolactone.

          -  Other organ fibrosis situations

          -  Malignant diseases

          -  Portal vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</investigator_affiliation>
    <investigator_full_name>Changqing Yang</investigator_full_name>
    <investigator_title>Professor in Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

